NASDAQ: IART
Integra Lifesciences Holdings Corp Stock

$18.78+0.38 (+2.07%)
Updated Jul 15, 2026
IART Price
$18.78
Fair Value Price
$30.57
Market Cap
$1.46B
52 Week Low
$8.70
52 Week High
$19.13
P/E
-2.91x
P/B
1.4x
P/S
0.44x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.64B
Earnings
-$495.80M
Gross Margin
51.9%
Operating Margin
-27.12%
Profit Margin
-30.1%
Debt to Equity
2.43
Operating Cash Flow
$71M
Beta
1.09
Next Earnings
Jul 30, 2026
Ex-Dividend
N/A
Next Dividend
N/A

IART Overview

Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine IART's potential to beat the market

BBuy
  • Stocks with a Zen Rating of Buy (B) had an average return of +17.17% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
C
IART
Ranked
#13 of 94

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
$11.97A
$42.29A
$28.60A
View Top Medical Device Stocks

Be the first to know about important IART news, forecast changes, insider trades & much more!

IART News

Overview

Due Diligence Score

Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IART scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

IART ($18.78) is undervalued by 38.56% relative to our estimate of its Fair Value price of $30.57 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
IART ($18.78) is significantly undervalued by 38.56% relative to our estimate of its Fair Value price of $30.57 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
IART is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IART due diligence checks available for Premium users.

Valuation

IART fair value

Fair Value of IART stock based on Discounted Cash Flow (DCF)

Price
$18.78
Fair Value
$30.57
Undervalued by
38.56%
IART ($18.78) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IART ($18.78) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IART is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

IART price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-2.91x
Industry
20.14x
Market
9.1x

IART price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.4x
Industry
2.99x
IART is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

IART's financial health

Profit margin

Revenue
$391.9M
Net Income
-$4.6M
Profit Margin
-1.2%
IART's Earnings (EBIT) of -$445.97M... subscribe to Premium to read more.
Interest Coverage Financials
IART's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$3.6B
Liabilities
$2.5B
Debt to equity
2.43
IART's short-term assets ($1.17B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IART's long-term liabilities ($2.19B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IART's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IART's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$9.8M
Investing
-$14.8M
Financing
$8.3M
IART's operating cash flow ($71.44M)... subscribe to Premium to read more.
Debt Coverage Financials

IART vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
IARTB$1.46B+2.07%-2.91x1.40x
INSPC$1.46B+2.75%11.32x1.84x
AHCOB$1.44B+3.93%-17.95x0.96x
ATECC$1.39B+0.78%-10.89x-260.01x
CNMDB$1.29B+2.49%24.18x1.27x

Integra Lifesciences Holdings Stock FAQ

What is Integra Lifesciences Holdings's quote symbol?

(NASDAQ: IART) Integra Lifesciences Holdings trades on the NASDAQ under the ticker symbol IART. Integra Lifesciences Holdings stock quotes can also be displayed as NASDAQ: IART.

If you're new to stock investing, here's how to buy Integra Lifesciences Holdings stock.

What is the 52 week high and low for Integra Lifesciences Holdings (NASDAQ: IART)?

(NASDAQ: IART) Integra Lifesciences Holdings's 52-week high was $19.13, and its 52-week low was $8.70. It is currently -1.83% from its 52-week high and 115.86% from its 52-week low.

How much is Integra Lifesciences Holdings stock worth today?

(NASDAQ: IART) Integra Lifesciences Holdings currently has 77,796,903 outstanding shares. With Integra Lifesciences Holdings stock trading at $18.78 per share, the total value of Integra Lifesciences Holdings stock (market capitalization) is $1.46B.

Integra Lifesciences Holdings stock was originally listed at a price of $4.44 in Dec 31, 1997. If you had invested in Integra Lifesciences Holdings stock at $4.44, your return over the last 28 years would have been 322.97%, for an annualized return of 5.29% (not including any dividends or dividend reinvestments).

How much is Integra Lifesciences Holdings's stock price per share?

(NASDAQ: IART) Integra Lifesciences Holdings stock price per share is $18.78 today (as of Jul 15, 2026).

What is Integra Lifesciences Holdings's Market Cap?

(NASDAQ: IART) Integra Lifesciences Holdings's market cap is $1.46B, as of Jul 16, 2026.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Integra Lifesciences Holdings's market cap is calculated by multiplying IART's current stock price of $18.78 by IART's total outstanding shares of 77,796,903.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.